Navigation Links
Abviva to Present at OneMedForum Sponsored by Stifel Nicolaus
Date:6/28/2010

SANTA BARBARA, Calif., June 28 /PRNewswire-FirstCall/ -- Abviva, Inc. (OTC: ABVV), a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, today announced they will be presenting at OneMedForum sponsored by Stifel Nicolaus.  Stifel Nicolaus, will be sponsoring the OneMedForum NY 2010. Stifel was recently ranked #1 overall out of 183 qualifying firms in  The Wall Street Journal's Best on the Street Survey for 2010.

"Abviva is excited to be included with other ground breaking biotech companies that will present at OneMedForum," said Barrett Evans, Abviva's CEO.  The goal of "2010 New York OneMedForum" is to connect private and public (microcap) medtech, biotech and health information companies with a global group of active healthcare investors.

Additional information can be found at www.onemedforum.com  

About Abviva

Abviva, Inc. is a biomedical company engaged in the innovation, development and commercialization of breast cancer related applications of Mammastatin, a growth inhibitory protein discovered at the University of Michigan Cancer Center that demonstrated anti-breast cancer properties. The discovery was developed into a simple breast cancer diagnostic blood test that demonstrated healthy women have high or normal levels of the protein and women with breast cancer have no detectable or very low levels of the protein. Abviva intends to commercialize the Mammastatin Serum Assay as a reference test through its wholly owned subsidiary laboratory under CLIA certification.  

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.


'/>"/>
SOURCE Abviva, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics
2. Abviva Details Patent Information for its Breast Cancer Risk Assessment Technology
3. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
4. Avicena Group to Present at Noble Financial Conference
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CEL-SCI to Present at the Noble Financial Conference
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
11. Strategic Diagnostics Updates Roth Conference Presentation Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... and LONDON , February 9, 2016 /PRNewswire/ ... tech replace paper and protect IP   ... laboratory notebook (ELN) will be rolled out in ... and development (R&D) and protect valuable IP. Users will be ... a specific researcher or experiment as part of the application, ...
(Date:2/9/2016)... Feb. 9, 2016 ... 2016", report provides in depth insights on ... around the Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. ... in various stages of development including Discovery, ... III and Preregistration. Report covers the product ...
(Date:2/8/2016)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced that it has entered into a ... Growth Capital, Inc. and Hercules Technology III, L.P. ... --> --> CytRx ... under the loan and security agreement.  The proceeds ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... Board of Directors. Todorow is the Executive Vice President for Corporate Services and ... Todorow oversees Finance, Accounts Payable, Payroll, Billing Operations, Treasury, Managed Care Contracting, Supply ...
Breaking Biology Technology:
(Date:2/3/2016)... Feb. 3, 2016 Vigilant Solutions announces today ... in Missouri solved two recent ... (LPR) data from Vigilant Solutions. Brian Wenberg ... which the victim was walking out of a convenience store and witnessed an ... to his vehicle, striking his vehicle and leaving the ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint ... that Rising Market Are you interested in ... forecasts revenues for checkpoint inhibitors. Visiongain,s report gives ... submarket, product and national level. Avoid falling ... what progress, opportunities and revenues those emerging cancer ...
(Date:2/1/2016)... February 1, 2016 Rising sales ... drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new technological ... size through 2020   ... with new technological advancements to drive global touchfree intuitive ...
Breaking Biology News(10 mins):